REG - EKF Diagnostics Hldg - Director/PDMR Shareholding

EKF Diagnostics HoldingsAnnouncement

08/11/2021 13:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211108:nRSH6822Ra&default-theme=true

RNS Number : 6822R  EKF Diagnostics Holdings PLC  08 November 2021

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Director/PDMR Shareholding

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care
business, announces that it has been notified that on 8 November 2021 Julian
Baines, Non-Executive Deputy Chairman,  sold a total of 250,000 ordinary
shares of 1 pence each in the Company ("Ordinary Shares") at a price of 80.76
pence per Ordinary Share.

 

Following this transaction, Julian Baines' total direct and indirect interest
in the Group is 1,605,288 Ordinary Shares representing approximately 0.35% of
the Group's total issued share capital.

 

The Notification of Dealing Form required in accordance with UK MAR is set out
below.

 

 

 EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Christopher Mills, Non-executive Chairman                      Tel: +44 (0)29 2071 0570
 Mike Salter, CEO
 Richard Evans, FD & COO

 Singer Capital Markets (Nominated Adviser & Joint Broker)                                   Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Tom Salvesen

 Investec Bank plc (Joint Broker)                              Tel: +44 (0)20 7597 4000
 Gary Clarence / Daniel Adams

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Julian Baines

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Deputy Chairman

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         EKF Diagnostics Holdings plc

 b)   LEI                                                          213800DXTF3EAUK1AR05

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          GB0031509804

 b)   Nature of the transaction                                    Sale of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     80.76p            250,000

 d)   Aggregated information

      - Aggregated volume                                          N/A - Single Transaction

      - Price

 e)   Date of the transaction                                      8 November 2021

 f)   Place of the transaction                                     London Stock Exchange - AIMX

 

 

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is a leading point-of-care diagnostics and central laboratory assay
manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose
and lactate analysers in regular use across more than 100 countries. EKF
specialises in developing tests for use in anemia and diabetes diagnosis and
management, as well as providing a portfolio of reagents for use in clinical
chemistry analysers.

 

EKF specialises in the development, production and worldwide distribution of
point-of-care analyzers and clinical chemistry reagents for use in hospital
and research laboratories, doctor's offices, blood banks and for in-field
anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and
has custom manufacturing facilities in the across sites in the US, UK and
Europe for a variety of life science products. Demand for contract
manufacturing of COVID-19 sample collection tests and kits has grown
dramatically during the pandemic, however the capabilities can be applied to
other areas of diagnostic testing, molecular disease and forensic test
manufacture.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBDBDBSUGDGBI